Cortisol Excess Marks a More Aggressive Adrenocortical Carcinoma Pattern
Severe hypercortisolism in adrenocortical carcinoma tracks with a higher risk of metastatic disease at diagnosis and a greater chance of recurrence or progression after treatment. In an international retrospective cohort of 101 patients with ACC-associated overt Cushing’s syndrome, baseline cortisol excess emerged as more than a biochemical abnormality. It behaved like a marker of tumor aggressiveness, one that may help identify patients facing a biologically more dangerous disease course from the outset.
ACC is uncommon, but when it drives cortisol excess the clinical picture changes fast. Hypercortisolism can deepen metabolic instability, amplify hypokalemia, and complicate both surgery and systemic therapy. It also reflects an endocrine-active tumor that is not merely present, but functioning, and that distinction often maps onto a more hostile clinical phenotype.
The study focused on real-world management of cortisol excess in routine practice and linked the degree of hypercortisolism with survival outcomes, including progression-free survival, disease-free survival, and overall survival. Investigators also assessed biochemical response to medical therapy, giving a practical view of what endocrinologists and oncologists actually achieve when they try to rein in cortisol secretion in this setting.
Baseline Cortisol Severity Carried Prognostic Weight
The central signal from the cohort was straightforward: higher baseline cortisol excess was associated with a greater risk of recurrence or progression. Older age, urinary free cortisol, hypokalemia, R0 resection status after surgery, and Ki-67 also independently predicted recurrence or progression and may help sharpen prognostic assessment. Overall survival, however, did not separate by cortisol severity in this analysis.
That split matters. A biomarker can influence relapse risk without immediately shifting overall survival, especially in a disease as aggressive and treatment-intensive as ACC. Recurrence and progression often determine the pace of later intervention, the need for repeated procedures, and the cumulative burden of endocrine toxicity long before mortality curves diverge.
The investigators also reported that adrenalectomy was associated with a high rate of biochemical remission in localized disease and still offered partial endocrine control when metastases were present. In bedside terms, resection remained the most effective tool for reducing cortisol burden when surgery was feasible, even if oncologic control was incomplete in advanced cases.
Why Cortisol May Mirror Tumor Biology
The association between cortisol excess and worse oncologic behavior is biologically plausible. Cortisol is a powerful glucocorticoid with broad immunomodulatory and metabolic effects, and sustained excess can worsen muscle loss, glucose intolerance, infection risk, and hypokalemia. In ACC, those systemic effects are superimposed on a tumor already capable of local invasion and early dissemination.
A functioning tumor that secretes substantial cortisol may be signaling a more differentiated endocrine phenotype or a larger viable tumor mass, either of which could correspond to higher oncologic risk. The study does not prove mechanism, but the relationship between baseline hormonal severity and later recurrence fits the clinical impression that endocrine activity can serve as a surrogate for aggressive disease biology.
Hypokalemia stood out as one of the independent predictors of recurrence or progression. In routine practice, severe potassium wasting often reflects intense cortisol exposure, and it may also complicate the perioperative course. When hypokalemia accompanies ACC-associated Cushing’s syndrome, the endocrine burden is not theoretical; it affects arrhythmia risk, weakness, and the urgency of cortisol control.
Surgery Still Anchors Control of Hypercortisolism
Adrenalectomy offered the clearest biochemical benefit in localized disease. Even in metastatic patients, surgery produced partial endocrine control, which can matter when cortisol excess itself threatens short-term stability. Lowering cortisol can improve blood pressure, potassium balance, glucose control, and functional status, all of which affect whether a patient can tolerate subsequent oncologic treatment.
The study’s retrospective design limits causal inference, and it cannot define the ideal sequence of endocrine and oncologic interventions. It does, however, reinforce a practical point: cortisol control should not be treated as a side issue in ACC. In a functioning tumor, controlling hormone excess is part of treating the cancer, not a separate task delegated to the margins of care.
Ki-67 also remained an independent predictor of recurrence or progression. In a disease where proliferation index already informs pathology review, combining Ki-67 with age, urinary free cortisol, hypokalemia, and surgical completeness may improve stratification at the moment decisions are being made about adjuvant therapy and surveillance intensity.
What the Findings Mean for Clinical Follow-Up
The most clinically useful message from the cohort is the need to identify cortisol excess early and treat it aggressively. Patients with ACC and overt Cushing’s syndrome face a dual burden: the malignancy itself and the endocrine consequences of uncontrolled glucocorticoid excess. Earlier recognition can reduce the interval between presentation and definitive intervention, while closer biochemical monitoring may help track response when surgery is incomplete or not possible.
The absence of an overall survival difference by cortisol severity should not be read as reassurance. Progression-free and disease-free outcomes still worsened with greater hypercortisolism, and those are the endpoints that drive repeated treatment, symptom burden, and escalating complexity of care. For a patient whose disease is already rare and highly aggressive, a stronger relapse signal at baseline is clinically meaningful.
This international study adds real-world support for using cortisol severity as part of the prognostic conversation in ACC-associated Cushing’s syndrome. It also leaves an obvious gap: prospective studies are still needed to define the prognostic role of cortisol excess more precisely and to determine how best to control hypercortisolism across the disease course. Until then, elevated cortisol, hypokalemia, and incomplete resection should be treated as warning signs that the tumor is behaving badly and may continue to do so after the first operation.